173 results about "Triterpenoid Compound" patented technology

The invention relates to the technical field of pharmaceutical preparations, in particular to a multiple nano emulsion adjuvant and a preparation method thereof. The multiple nano emulsion adjuvant is prepared from 2.73 to 6.37 g of an oil phase matrix based on 100 g of a raw material system, 0.10 to 0.25 g of a sterol compound; 0.212 to 0.424 g of a nonionic surfactant; 0.00050 to 0.00200 g of a triterpenoid saponin type active adjuvant; 0.010 to 0.020 g of an anionic polymer modifier; 0.005 to 0.015 g of a cationic polymer modifier; 70-90 g of a buffer solution; the total mass of the raw materials is 100 g. The nano emulsion adjuvant prepared by the invention can be stored for 6 months at 2-8 DEG C under a low sterol condition, the particle size change does not exceed + 5%, no crystallization or layering is generated, and the stability of the active adjuvant is remarkably improved.

A method for preparing nanoparticles of triterpenoid small molecules co-assembled with Ce6 and copper ions wrapped in cancer cell membranes and its application. The present invention prepares a pure natural co-assembled nanotransmission system with new morphological characteristics and multiple biological activities - terpenoid compound and photosensitizer co-assembled nanoparticles. In the composite nanoassembly, triterpenoid compounds and photosensitizer Ce6 are assembled into nanoparticles, providing effective and safe chemotherapy and photodynamic therapy. Subsequently, Cu is complexed on the surface of the nanoparticles. 2+ , when Cu is introduced 2+ When activated, the reduced PDT effect caused by excessive glutathione in the tumor consuming reactive oxygen species can be counteracted. Furthermore, it can enhance CDT therapy through a Fenton-like catalytic reaction with overexpressed H₂O₂ at the tumor site. Finally, these molecules are encapsulated by the tumor cell membrane. By constructing CM@OABACe6 / CuNPs with homologous targeting, a triple synergistic platform for cancer treatment using PDT, chemotherapy, and CDT has been created.

This invention discloses tea saponin E3, its isolation and purification method, and its application as a killer of moon jellyfish polyps, belonging to the field of natural product chemistry. The structure of tea saponin E3 is shown below. Derived from plants, it is a natural triterpenoid saponin compound. Compared with tea saponin, it exhibits stronger killing activity against moon jellyfish polyps. Furthermore, its single component and well-defined structure facilitate standardized application and evaluation of potential ecological risks in the biocontrol of moon jellyfish polyps.

The invention discloses an engineered glycosyl transferase and application thereof in efficient preparation of triterpenoid saponin. The engineered glycosyl transferase is obtained by mutating serine at the 15th site of UGT74AC1 enzyme into alanine, mutating histidine at the 47th site into aspartic acid, mutating leucine at the 48th site into valine, mutating alanine at the 180th site into serine, mutating histidine at the 180th site into aspartic acid, mutating histidine at the 180th site into aspartic acid, mutating histidine at the 180th site into aspartic acid, mutating histidine at the 180th site into aspartic acid The mutant is obtained by mutating serine at the 332 site into proline, phenylalanine at the 367 site into tryptophan and lysine at the 420 site into arginine. According to the invention, the glycosyl transferase with high catalytic activity is obtained by modifying an enzyme engineering technology, and good application of the glycosyl transferase in synthesis of triterpenoid saponin is realized. The glycosyl transferase disclosed by the invention can also be coupled with sucrose synthase, or coupled with N-acetylhexosamine kinase and N-acetylglucosamine-1-uridine phosphate transferase, and acetylglucosamine is used as a glycosyl donor, so that cascade production of triterpenoid saponin with lower cost and higher efficiency is realized.

The invention discloses arabinose glycosyl transferase PnUGT73B4 and application thereof to preparation of panax japonicus saponin IV, the amino acid sequence of the arabinose glycosyl transferase is shown as SEQ ID NO: 1, under the catalysis of the arabinose glycosyl transferase PnUGT73B4, UDP-arabinose is added to a glucuronic acid group on the C3 site of panax japonicus saponin IVa, and the panax japonicus saponin IV is generated; according to the method, the requirement for raw material plants can be reduced, agricultural land is saved, the product is single, preparation of the panax japonicus saponin IV is facilitated, the biosynthesis route of oleanane type triterpenoid saponin is analyzed, and a breakthrough solution is provided for biosynthesis of the panax japonicus saponin IV.

The present invention discloses a fermentation method for Antrodia camphorata mycelium and an auxiliary composition for fermentation of Antrodia camphorata. The method provided by the present invention comprises the following steps: S1. subjecting an Antrodia camphorata strain to liquid fermentation for 60-120 hours; S2. adding precursors to the fermented Antrodia camphorata strain liquid fermentation broth, and continuing the fermentation for more than 120 hours to obtain Antrodia camphorata mycelium; the precursors being coenzyme Q0, p-hydroxybenzoic acid, linalool, and α-terpineol, and the fermentation broth after adding the precursors having a coenzyme Q0 content of 100-500 mg / L, a p-hydroxybenzoic acid content of 20-300 mg / L, a linalool content of 0.1-0.5 mg / L, and an α-terpineol content of 0.3-0.7 mg / L. This method adds precursor substances of specific composition and concentration to the liquid fermentation broth of Antrodia cinnamomea at a certain time and combines them with each other, which is beneficial to the secondary metabolism of Antrodia cinnamomea and promotes the synthesis of triterpenoid compounds, thereby increasing the yield. Compared with the existing technology, the yield of triterpenoid compounds produced by Antrodia cinnamomea mycelium is increased, the culture cycle is shortened, and it is more suitable for large-scale production.

The invention belongs to the field of traditional Chinese medicine chemistry and natural product separation, and particularly relates to extraction and separation of a novel triterpenoid compound 25-Etherxy-dammar-20 (22) Z-ene-3beta, 6alpha, 12beta-triol and application of the novel triterpenoid compound 25-Etherxy-dammar-20 (22) Z-ene-3beta, 6alpha, 12beta-triol in myocardial protection drugs. The compound is named as 25-Etherxy-dammar-20 (22) Z-ene-3beta, 6alpha, 12beta-triol, and the structural formula of the compound is shown in the description. The invention provides an extraction and separation method of the compound. The extraction and separation method mainly comprises the following steps: sequentially carrying out solvent extraction, macroporous adsorption resin enrichment, silica gel column chromatography, ODS medium-pressure column chromatography, high performance liquid chromatography separation and purification and the like on ginseng and other traditional Chinese medicine processed products and hydrolysates. The structure of the compound is determined through comprehensive analysis of a high-resolution mass spectrum (HRMS), one-dimensional nuclear magnetic resonance (1H NMR, 13C NMR) and a two-dimensional nuclear magnetic resonance spectrum (such as HSQC, HMBC, ROESY and the like), and the compound is a newly discovered dammarane type triterpene compound. Experiments show that the compound and the composition thereof have a remarkable protection effect on myocardial cell hypoxia / reoxygenation reperfusion injury, and can be used for preparing drugs for preventing or treating myocardial ischemia reperfusion injury and other related diseases.

The invention relates to the technical field of biology, and discloses high-activity black fungus dry powder as well as a preparation and a preparation method thereof, and the black fungus dry powder is prepared by the following steps: selecting high-quality black fungus in northeast as a raw material, and performing primary washing, fine washing, color protection and draining pretreatment at normal temperature in a dark place; carrying out compound enzymolysis by using cellulase and pectinase under a low-temperature acidic condition; power frequency ultrasonic-assisted extraction is set; drying under a vacuum freezing condition until the moisture is less than or equal to 8%; according to the process disclosed by the invention, the raw materials are selected, and multi-step cooperative treatment of low-temperature enzymolysis wall breaking, ultrasonic enhanced mass transfer, vacuum freeze-drying keep-alive and sterile post-treatment is combined, so that active ingredients of polysaccharide, melanin and triterpenoids are fully reserved, and the process is simple and convenient to operate, low in cost and suitable for large-scale production. Therefore, the extraction efficiency and bioavailability are improved, the hygienic safety and storage stability of a finished product are guaranteed, and a foundation is laid for subsequent development of diversified black fungus preparations.

The invention relates to a triterpenoid saponin compound, a preparation method thereof and application of the triterpenoid saponin compound in preparation of anti-neuroinflammation drugs. The triterpenoid saponin compound has a structure as shown in a formula I. An in-vitro anti-neuroinflammation activity experiment proves that the triterpenoid saponin compound has an obvious inhibition effect on lipopolysaccharide (LPS)-induced BV2 cell inflammation, and can be used as a novel anti-neuroinflammation drug and a neurodegenerative disease treatment drug. Formula I

The invention provides an antrodia camphorata sporocarp extract, which is prepared from the following raw materials in parts by weight: 20 to 24 parts of wild ganoderma lucidum extract, 8 to 12 parts of herba taraxaci and 8 to 12 parts of bolete. The antrodia camphorata sporocarp extract disclosed by the invention contains various physiologically active components such as triterpenoids, polysaccharides, superoxide disproportionated enzymes, adenosine, proteins (containing immune proteins), vitamins, trace elements, nucleic acid, lectin, amino acid, sterols, lignin, blood pressure stabilizing substances and the like; the traditional Chinese medicine composition can relieve various tumors such as hangover, gastrointestinal discomfort, heatstroke, hypertension, virus infection, diabetes mellitus, nephritis, liver cirrhosis and liver cancer, has the effects of resisting oxidation, resisting inflammation, inhibiting hypertension, protecting liver nerves, inhibiting tumor growth and the like, can bidirectionally regulate immunity and protect the liver, can also treat tumors at multiple targets, and has a wide application prospect. The discomfort of a patient in an anti-tumor process is reduced.

The application relates to the technical field of natural medicinal chemistry, and specifically discloses a triterpenoid compound and application, and a preparation method of the compound. The preparation method comprises the following steps: drying and crushing schisandra chinensis roots to obtain dried and crushed schisandra chinensis roots, extracting the dried and crushed schisandra chinensis roots by using 70% ethanol water solution under negative pressure cavitation, combining and concentrating the extract to obtain a crude extract, separating the crude extract by using a D101 macroporous adsorption resin, eluting the crude extract by using water, 30% ethanol, 70% ethanol and 90% ethanol in sequence, collecting a 70% ethanol elution part, performing MCI column chromatography on the 70% ethanol elution part, performing gradient elution on the 70% ethanol elution part by using methanol-water, collecting a depigmentation sample, performing ODS column chromatography on the depigmentation sample, performing gradient elution on the depigmentation sample by using water-methanol, collecting a target component, and purifying the target component by using a preparative high performance liquid chromatograph to obtain the target compound. The application separates a novel triterpenoid compound from schisandra chinensis roots for the first time, expands the development range of medicinal resources of schisandra chinensis plants, simultaneously provides a novel structure mother nucleus and a candidate active molecule for anticancer drug research and development, and enriches the research and development reserves of antitumor natural medicines.

The application provides a microcapsule of triterpenoid compounds of Radix Morindae Officinalis and a preparation method thereof. The preparation method is as follows: taking Radix Morindae Officinalis powder as raw material, first extracting with ethanol under ultrasonic, then extracting with ethyl acetate to obtain triterpenoid compounds of Radix Morindae Officinalis; mixing malt dextrin and gum arabic, dissolving in water to obtain a wall material solution; adding the triterpenoid compounds of Radix Morindae Officinalis into the wall material solution, then adding glycerol monostearate, stirring to obtain an emulsion; spray drying the emulsion to obtain the microcapsule of triterpenoid compounds of Radix Morindae Officinalis. The application also provides application of the microcapsule in preparation of antibacterial drugs or antioxidant active drugs. The extracted triterpenoid compounds of Radix Morindae Officinalis and the microcapsule based on the compounds have good antibacterial and antioxidant activities; through the microencapsulation method, the microcapsule has good water solubility, can avoid being attacked by gastric acid, has the effect of being released fully in the small intestine, and has the advantages of high sustained-release stability and high effective component utilization rate.

The application discloses a norchizhiol triterpenoid compound, a preparation method and application thereof. The norchizhiol triterpenoid compound norchizhiol A can be quickly prepared from Ganoderma lucidum. The test proves that the norchizhiol A can inhibit the accumulation of triglyceride in the differentiation process of 3T3L1 preadipocytes. The norchizhiol A can also effectively reduce the weight increase and liver coefficient of high-fat-diet-induced obese mice, regulate the blood lipid level of the obese mice, and significantly intervene and improve the lipoprotein distribution of the body. The compound can be used for preparing anti-obesity and lipid-lowering medicines.

The present invention belongs to the field of plant genetic engineering technology, and in particular to the application of a Centella asiatica glycosyltransferase gene in catalyzing the glycosylation of asiatic acid and madecassic acid. The nucleotide sequence of the gene is as shown in SEQ ID No.1, and the protein encoded by it can catalyze the C-28 position of asiatic acid and madecassic acid to carry out glucose group modification to produce asiatic acid monoglucoside and madecassic acid monoglucoside, and prefers catalysis madecassic acid. The present invention, by building a metabolic regulatory network, widely and accurately screens the above-mentioned gene, resolves the glycosylation process of catalyzing asiatic acid and madecassic acid, for the in vitro synthesis of Centella asiatica triterpenoid saponins and industrial production process to improve asiatic acid and madecassic acid glycosylation efficiency and asiaticoside and madecassin yield provide important reference basis, and provide important theoretical support for large-scale production of Centella asiatica active saponins.

Sesterterpenoid compounds and an extract L01 of Leucosceptrum canum, and use thereof in treatment of psoriasis are provided, belonging to the technical field of natural medicinal chemistry. The sesterterpenoid compound of the Leucosceptrum canum has a structure shown in any one of Formulas 9 to 12, which shows a highly rare backbone type, exhibits anti-inflammatory and immunosuppressive activities, and can be used in preparation of an anti-inflammatory drug and an immunosuppressive drug. A Leucosceptrum canum extract L01 having compounds 1 to 12 as characteristic ingredients, and use thereof in preparation of an anti-inflammatory drug and an immunosuppressive drug are further provided.

The application provides a varicella-zoster virus vaccine and application thereof, and belongs to the technical field of vaccines.The varicella-zoster virus vaccine comprises liposome nanoparticles, zoster virus glycoprotein E and an adjuvant encapsulated in the liposome nanoparticles.The adjuvant comprises triterpenoid saponins.In the application, the zoster virus glycoprotein E (gE) is wrapped by the liposome nanoparticles, which can effectively promote antigen-presenting cells to phagocytose and efficiently deliver the antigen, and realize sustained stimulation of the vaccine to the body to produce a specific cellular immune response against VZV-gE.The triterpenoid saponins used in the application can effectively realize cross-presentation of the antigen zoster virus glycoprotein E and induce an antigen-specific cellular immune response.In addition, the cholesterol rich in the liposome nanoparticles can effectively neutralize the cytotoxicity of the triterpenoid saponins, ensuring the safety of the vaccine.

The application provides a key enzyme involved in glycosylation modification of triterpene saponins, and an application thereof, and belongs to the technical field of genetic engineering. The glycosyltransferase gene is screened based on the omics research of the base plant of traditional Chinese medicine Duanxueliu, i.e. clinopodium gracile, and a pET28a-MBP-CcGT-g51295 prokaryotic expression vector is constructed to successfully obtain the glycosyltransferase. It is found that the glycosyltransferase can catalyze Saikogenin A and Saikogenin F to generate Prosaikogenin A and Prosaikogenin F respectively by using a glycosyl donor UDP-fucose; can catalyze Saikogenin A to generate clinopodiside I and clinopodiside X by using UDP-glucose; can catalyze Prosaikogenin A to generate Saikosaponin B1, Saikosaponin c1 and Saikosaponin X by using UDP-glucose; and can catalyze Prosaikogenin F to generate Saikosaponin A and Buddlejasaponin IV by using UDP-glucose, which reveals the catalytic function of the glycosyltransferase and provides a gene component for the biological research of triterpene saponins, and solves the problem of biological resources of rare saponins.

The present application provides vaccines comprising an inactivated influenza virus and an adjuvant comprising a triterpenoid saponin, a sterol, and an immunostimulatory oligonucleotide comprising CpG. Also provided are methods of using such vaccines.

To provide wound-healing formulations containing solid birch bark extracts that may be applied to the skin without worsening the patient's condition.SOLUTION: A solid birch bark extract comprises at least about 70 wt.% of betulin, and one or more triterpenes selected from the group consisting of betulinic acid, oleanolic acid, erythrodiol, and lupeol.SELECTED DRAWING: None

The invention discloses a pharmaceutical composition for resisting non-small cell lung cancer as well as a preparation method and application of the pharmaceutical composition, belongs to the technical field of antitumor drugs, and mainly solves the technical problem that application is affected due to the fact that an Iridobelamal A compound has high toxicity to normal lung cells. The composition provided by the invention comprises the following active components: an iridoaldehyde triterpenoid compound Iridobelamal A and a flavonoid compound tectorigenin, the molar ratio of the Iridobelamal A to the tectorigenin is 1: 2-1: 5, the molecular formula of the Iridobelamal A is C30H50O4, the molecular formula of the tectorigenin is C16H12O6, and the composition and a pharmaceutical carrier are prepared into an oral preparation or an injection. The composition is used for preparing a medicine for treating non-small cell lung cancer by neutralizing triterpene toxicity and synergistically enhancing anti-tumor activity.

The invention relates to the technical field of medicine preparation, and provides a probiotic ganoderma lucidum yeast tablet which comprises 30-50% of ganoderma sinense extract; 20%-35% of yeast powder; 10%-25% of microcrystalline cellulose; 1%-3% of magnesium stearate; the content of polysaccharide in the ganoderma sinense extract is greater than or equal to 15%, the content of triterpenoids in the ganoderma sinense extract is greater than or equal to 8%, and the flavoring agent is selected from one or a combination of more of menthol, stevioside and citric acid. The probiotic ganoderma lucidum yeast tablet is rich in high-content ganoderma sinense extract and yeast powder, in the ganoderma sinense extract, polysaccharide regulates the immune function, enhances the body resistance and assists in gastric mucosa repair, triterpenoids have anti-inflammatory and antioxidant activity and effectively relieve symptoms of patients, the yeast powder can promote food digestion and absorption and improve the gastrointestinal function, and the health care effect is achieved. The main components of the product are all natural, the safety is high, and the toxic and side effects are greatly reduced compared with traditional chemical synthesis drugs.

The application discloses a triterpenoid compound, and the structure is (3β, 6α, 10α, 12α, 16β, 24E)-4-methylol-6, 12-bis(acetyloxy)-3, 10, 16-trihydroxy-9, 19-cyclo-9, 10-secolanosta-9(11), 24-dien-26-yl β-D-glucopyranoside. The application obtains a new monomer compound with anticancer activity by separating and screening monomer components in leaf of Astragalus membranaceus Bge. var. mongholicus (Regel) H. The application provides a theoretical basis for further in-depth research on components and medicinal activities of the leaf of Astragalus membranaceus Bge. var. mongholicus (Regel) H, and also expands natural plant resources of anticancer drugs.

Provided are a Gynostemma pentaphyllum-derived triterpenoid saponin compound and a use thereof in the preparation of anti-fatigue products. The provided triterpenoid saponin compound is selected from one of compounds 1-29. Also provided are a use of a triterpenoid saponin compound as represented by general formula I in the preparation of anti-fatigue products. Experiments show that the Gynostemma pentaphyllum-derived triterpenoid saponin compound has significant anti-fatigue activity and can be used for preparing anti-fatigue products.

The invention belongs to the technical field of health-care products, and discloses an oligosaccharide selenium ganoderma lucidum capsule for enhancing immunity and inhibiting tumors and a preparation method, and the content of the capsule is prepared from the following raw materials in parts by mass: 150-160 parts of collagen, 80-85 parts of chitosan oligosaccharide, 110-130 parts of ganoderma lucidum extract, 45-55 parts of selenium-enriched yeast, 50-80 parts of maltodextrin and 7-10 parts of magnesium stearate. The skin barrier can be improved, intercellular communication can be promoted and local immune response can be stimulated through low-molecular peptide of collagen, intestinal flora balance can be adjusted through chitosan oligosaccharide, probiotic growth can be promoted, mucous membrane immunity can be further improved, and finally immune cells can be effectively activated through polysaccharide and triterpenoids in the ganoderma lucidum extract, so that the immunity of a human body is improved. The activity of macrophages and natural killer cells is enhanced, and the multi-target and multi-path immune regulation effect can effectively enhance the defense of the body to pathogenic microorganisms.

This invention discloses an antitumor natural drug composition based on Norway maple and its preparation method, relating to the field of biomedical technology. The compound is selected from at least one of the following structures: 3-O-[β-D-glucopyranosyl-(1→4)-[β-D-galactopyranosyl-(1→2)]]-β-D-glucopyranoside-21-O-acetyl-22-O-angeloyl yrutile alcohol, with the molecular formula C2. 55 H 86 O 23 This invention isolates a class of triterpenoid saponins with a rutinol skeleton from the bark of Norwegian maple, enriching the chemical composition library of maple species. The compounds contain unique oligosaccharide chains and diacyl substitution patterns at C-21 and C-22. One compound has a rare branched acyl group (3-hydroxy-4-methylhexanoyl) at C-21, while the other compound contains an arabinofuranose unit in its C-3 trisaccharide chain. These structural features are rare in natural products and demonstrate excellent structural novelty.

To provide a composition for promoting tight junction formation that promotes formation of tight junctions between epithelial tissue cells.SOLUTION: A composition for promoting tight junction formation for promoting formation of tight junctions between epithelial tissue cells, contains triterpenes and skim milk and / or wheat gluten, thereby solving the problem to be solved.SELECTED DRAWING: None

The invention relates to the technical field of plant extraction, in particular to a method for extracting poria cocos triterpenoids based on a supramolecular solvent and application of the poria cocos triterpenoids. The method comprises the following steps: extracting poria cocos powder by adopting a supramolecular solvent, carrying out solid-liquid separation, and collecting to obtain a liquid containing triterpenoids; the supramolecular solvent consists of a hydrogen bond acceptor, a hydrogen bond donor and water; the hydrogen bond acceptor comprises at least one of betaine and menthol, and the hydrogen bond donor comprises at least one of 1, 2-butanediol, thymol, aminobutyric acid, lactic acid and camphor. The method has the advantages of being high in extraction rate, more environmentally friendly and higher in whitening and anti-inflammatory activity.

The invention provides a triterpenoid compound in ganoderma sinensis fermented mycelium. The structural formulas of the triterpenoid compound are structural formulas 1, 3, 4 and 7. The invention further provides application of the triterpenoid in the ganoderma sinensis fermented mycelium as a medicine for preventing or treating inflammation. The triterpenoid in the ganoderma sinensis mycelium is one or more of compounds with structural formulas 1-8. The triterpenoids separated and purified from ganoderma sinensis mycelia are subjected to anti-inflammatory activity test for the first time, and the results show that the compounds with the structural formulas 1-8 can inhibit release of TNF-alpha and IL-6 and have remarkable anti-inflammatory activity.

The invention provides a method for accurately evaluating ganoderma lucidum spore powder triterpenes. The method comprises the following steps: (1) pretreating ganoderma lucidum spore powder; (2) an ultra-high performance liquid chromatography detection step; (3) obtaining mass spectrum information of the compound; (4) establishing an ultra-high performance liquid chromatography-triple quadrupole mass spectrometry combined analysis method; and (5) a data analysis step. According to the method for accurately evaluating the content of the triterpenes in the ganoderma lucidum spore powder, provided by the invention, accurate analysis of the triterpenes in the ganoderma lucidum spore powder is realized, and a reliable detection technology is provided for evaluation of ganoderma lucidum spore powder raw materials and development of related products.

This invention provides methods for the production of glycosylated triterpenoids which function as endosomal escape enhancers. Specifically, the invention provides UDP glycosyltransferases (UGTs) useful for the biosynthesis of these glycosylated triterpenoid saponins. The invention also provides in vitro systems and plant extracts comprising UDP glycosyltransferases and sapofectosid precursors.